Our governance

Ian is currently Director of Quality at NHS Blood and Transplant. He is an Executive Director and Board Member with significant strategic leadership experience in healthcare organisations in both public and private sectors. He has a strong background in corporate leadership of quality, regulatory affairs, corporate governance, assurance, risk, health and safety, environment management and continuous improvement.

Ian worked as a senior executive in a number of global organisations including NCR, AT&T, RIL and BAT with a business sector focus on Engineering, Technology and Fast Moving Consumer Goods. This included various Corporate and Board roles covering Strategy, HR, IT, Quality and Marketing Services in the UK, USA, Asia Pacific, Middle East, and mainland Europe.

Ian Black is the founder and a Director of Arch Management Consultants focusing on Organisation Strategy, HR Leadership, Change Management, Remuneration, Talent Management, Governance and Performance Improvement. In this capacity he has provided consulting services to organisations in various sectors including, insurance, consumer goods, aviation, pharmaceuticals and technology.

Ian has served as a Non- Executive Director in both the public and private sectors where he has been a Member or Chair of Board Committees such as Audit, Remuneration, Nominations and Strategy. Appointments included LMC, LG, Remploy Services, MLCSL and QIB. He is also a Director of BSH, Ltd an international equestrian business.

Rona is a fellow of the Institute of Chartered Accountants with nearly 40 years experience in leading financial teams in both the public and private sector. During her early career Rona worked in international finance managing the Finance and Treasury teams for an oil and gas shipping business followed by roles at Sotheby’s as their European Finance Director and  Ofcom the newly formed communications regulator. More recently Rona was the Chief Operating Officer at Sport England, the lottery distributor, where additional responsibilities included grants management, Commercial and IT as well as contributing to the development of the organisations strategy.

Jon was a senior Partner at Brunswick Group LLP, a leading international communications consultancy, where he advised the Boards of Directors of global groups on strategic communications and corporate reputation. His particular focus was on clients in the pharmaceutical, biotechnology and agriculture industries.

Professor Vince Emery is Emeritus Professor of Translational Virology at the University of Surrey and holds an Honorary Professorship in Virology at UCL

Prof Emery graduated with a first class BSc in Biochemistry with Chemistry from the University of Southampton and then undertook his PhD research in mechanistic biochemistry under the auspices of Professor Muhammad Akhtar FRS. His interests in virology started when he undertook a postdoctoral fellowship at the NERC Institute of Virology at Oxford, where he worked on transcription termination in phleboviruses, determining the attenuation in a vaccine strain of Rift Valley Fever Virus used by the US Army, and developing the World’s first baculovirus multiple expression vector system which was subsequently patented and licensed. 

He was appointed Lecturer in Virology at the Royal Free Hospital School of Medicine in 1988 and was promoted to Professor of Virology at UCL in 2000. Over the last 30 years, his research has aimed to provide an interdisciplinary approach to understanding viral infections in immunocompromised hosts such as HIV-infected patients and transplant recipients. His particular interests have focused on cytomegalovirus in solid organ and stem cell transplant recipients and in newborns (especially in Africa) by combining viral replication methods with assessment of the immune response and mathematical biology approaches to improve patient management. During his career he has obtained in excess of £29 million of grant money from Government agencies in the UK and USA, charitable organisations, and the private sector and has a an H-index of 67 and his work has been cited over 14,000 times.

Prof Emery is a Deputy Director of a UCL led consortium called i-sense (www.i-sense.org.uk) which is supported by £14 million grants from EPSRC and focuses on developing novel sensing methods for infectious diseases.  Prof Emery is a fellow of the Royal Society of Biology and was selected as a Fellow of the American Society of Transplantation in 2017 for his contribution to infectious disease research and its impact on patients following transplantation. 

Prof Emery has published 238 research articles, reviews, and books including a patient’s guide to cytomegalovirus.  In addition, Prof Emery is a named inventor on five patents in the area of biotechnology and molecular diagnostics, with the molecular diagnostics patent for cytomegalovirus detection licenced to Public Health England.

  Emma Griffin has over 25 years professional experience across a multitude of sectors in cyber security, technology, and regulatory compliance. Experienced in all facets of cyber security including data protection, cloud, infrastructure and application security, preventing business disruption, cyber fraud and intellectual property theft. She is a trusted advisor to senior leadership, risk and audit committees, and company boards. She participates on several advisory boards to influence and drive cyber security development and solution innovation and regularly participates in industry and regulatory forums as an advisor and speaker. Emma is actively involved in promoting diversity and inclusion, and seeks to encourage careers in science and technology to minority groups.

Emma has a Master’s degree in Information Security from Royal Holloway, University of London.

  Alison Hardy is a solicitor and partner with City law firm Ashurst LLP where she leads the real estate dispute resolution practice. She is the HR partner for the dispute resolution practice at Ashurst, which involves overseeing the recruitment and retention of talent and the appraisal, review and remuneration systems for the department. She is a former Chair of the Property Litigation Association, having earlier chaired the association's website and marketing committee. She provides strategic risk management and dispute resolution advice in relation to complex, high value commercial real estate related issues and has a particular interest in property-related insolvency, telecoms and technology fields. She is experienced in all aspects of commercial real estate including landlord and tenant, development, investment, capital markets, strategic land assembly, infrastructure, rail, owner occupiers, retail, utilities, telecoms, data centres and logistics. She is a member of the RICS Dilapidations Forum and is chairing the UK RICS dilapidations conference in 2021. She speaks at conferences and is regularly quoted in both the Estates Gazette and Property Week, and has been quoted in other reputable publications such as The Times and The Financial Times. Alison is actively involved in diversity and inclusion, and is the partner sponsor of Ashurst's Social Mobility and Inclusion network, which is working to remove barriers to entry into and progression within the legal profession.

 Prior to his retirement in 2020, Dr Paul Logan was a Senior Civil Servant in the Health and Safety Executive (HSE) which he had joined as a regulatory scientist. He subsequently trained as a specialist inspector with responsibility for inspection of high containment laboratories. During his time in HSE he chaired a number of industry/government committees, as well as representing the UK on a European Medicines Agency working group on Gene Therapy, and a World Health Organization group developing guidelines for the manufacture of pandemic flu vaccines. In his final post he was Director of the division in HSE with responsibility for regulation of major hazards industries, including chemical manufacturing, oil refineries, explosives manufacture and storage, and high containment laboratories. 

Roger was a senior civil servant in the Department for Business Innovation and Skills. In his final post before retirement in 2011 he was responsible for the strategic financial management of the Government's £6 billion per annum Science and Research Budget.

Professor Stephenson became Chair on 1 April 2019. He has had a distinguished research career, with a long-standing interest in the interaction between virus infection and the immune system. He holds honorary professorships at the London School of Hygiene and Tropical Medicine and the University of Liverpool and is an Independent Scientific and Technical Advisor (ISTA) for the Surgeon General.

Jane has over 30 years of experience of all aspects of strategic financial planning, financial management, financial accounting, systems and processes. As a result of her roles she has a working knowledge of government departments, funding councils, academia and the pharmaceutical industry. Her last position was as the Director of Finance and Corporate Services at the Diamond Light Source, the UK’s national synchrotron science facility.

Professor Jeffrey Almond is an Oxford Martin Visiting Fellow with the Oxford Martin Programme on Vaccines and was Former Vice President and Head of Discovery Research and External R&D at Sanofi Pasteur and Visiting Fellow at the William School of Pathology, University of Oxford.

He was lecturer at the University of Leicester from 1979-85 and Professor of Microbiology at the University of Reading 1985-99. He has published extensively, especially in the field of Virology.

His scientific contributions include the first demonstration that a single gene can determine host range of influenza virus– a finding highly relevant to understanding evolution of new pandemic strains; completion of the genetic map of an avian influenza virus, and the first detailed description of the proteins of Influenza B virus. He has also made major contributions to our understanding of polio virus and its vaccines.

In 1985 as a young academic, Almond won the Fleming Award for outstanding contributions to microbiological research by a young microbiologist in the UK, and the pace and extent of his contributions have not diminished. In his previous role he was responsible for the scientific rationale underpinning approximately 30 vaccine projects covering viruses, bacteria and eukaryotic parasites.

During the BSE crisis he served as coordinator of the BBSRC’s Research programme on the Spongiform Encephalopathies and was a member of the Government’s Spongiform Encephalopathies Advisory Committee (SEAC). He is an Elected fellow of the American Academy of Microbiology and in 1999 was awarded the Ivanovsky Medal for “Contributions to the Development of Virology” by The Scientific Council of Virology of Russian Academy of Medical Sciences.

Professor Persephone Borrow is a viral immunologist whose research interests centre on understanding virus-immune system interactions and their roles in determining the balance between virus clearance versus viral persistence and associated pathogenesis.

She obtained a BA(Hons) degree in Natural Sciences from the University of Cambridge, UK and stayed at Cambridge to study for a PhD under the supervision of Professor Tony Nash. After this she carried out postdoctoral research with Professor Michael Oldstone at The Scripps Research Institute, USA, where she subsequently progressed to become an Assistant Member. She then returned to the UK to lead the Viral Immunology Group at the newly-established Edward Jenner Institute for Vaccine Research, and in 2005 joined the Nuffield Department of Medicine at the University of Oxford, where she currently holds the position of Professor of Viral Immunology and is also a Jenner Institute Investigator.

Her research team, based at the NDM Research Building on Oxford University’s Old Road Campus, focuses mainly on analysis of CD4 and CD8 T cell responses and innate responses in HIV infection, aiming to inform the development of vaccines and other prophylactic and therapeutic strategies based on modulation of T cell and innate immunity; and is also performing some comparative studies of innate responses in other human virus infections including herpesvirus infections.  Her group’s research is largely funded by the MRC and the US NIH. 

Professor Vince Emery is Emeritus Professor of Translational Virology at the University of Surrey and holds an Honorary Professorship in Virology at UCL

Prof Emery graduated with a first class BSc in Biochemistry with Chemistry from the University of Southampton and then undertook his PhD research in mechanistic biochemistry under the auspices of Professor Muhammad Akhtar FRS. His interests in virology started when he undertook a postdoctoral fellowship at the NERC Institute of Virology at Oxford, where he worked on transcription termination in phleboviruses, determining the attenuation in a vaccine strain of Rift Valley Fever Virus used by the US Army, and developing the World’s first baculovirus multiple expression vector system which was subsequently patented and licensed. 

He was appointed Lecturer in Virology at the Royal Free Hospital School of Medicine in 1988 and was promoted to Professor of Virology at UCL in 2000. Over the last 30 years, his research has aimed to provide an interdisciplinary approach to understanding viral infections in immunocompromised hosts such as HIV-infected patients and transplant recipients. His particular interests have focused on cytomegalovirus in solid organ and stem cell transplant recipients and in newborns (especially in Africa) by combining viral replication methods with assessment of the immune response and mathematical biology approaches to improve patient management. During his career he has obtained in excess of £29 million of grant money from Government agencies in the UK and USA, charitable organisations, and the private sector and has a an H-index of 67 and his work has been cited over 14,000 times.

Prof Emery is a Deputy Director of a UCL led consortium called i-sense (www.i-sense.org.uk) which is supported by £14 million grants from EPSRC and focuses on developing novel sensing methods for infectious diseases.  Prof Emery is a fellow of the Royal Society of Biology and was selected as a Fellow of the American Society of Transplantation in 2017 for his contribution to infectious disease research and its impact on patients following transplantation. 

Prof Emery has published 238 research articles, reviews, and books including a patient’s guide to cytomegalovirus.  In addition, Prof Emery is a named inventor on five patents in the area of biotechnology and molecular diagnostics, with the molecular diagnostics patent for cytomegalovirus detection licenced to Public Health England.

Professor Gary Entrican is an immunologist who has specialised in the development of vaccines and diagnostic tests for the control of infectious diseases of ruminant livestock. He did his BSc Hons and PhD in Immunology at The University of Glasgow and then moved to The Moredun Research Institute (MRI) in Edinburgh to investigate the immunological basis of pestivirus persistence in sheep. He has developed many immunological tools and technologies, including kits for in vitro differentiation of ruminant dendritic cells and cytokine ELISAs. He produced a panel of pestivirus-specific monoclonal antibodies and developed a first-generation diagnostic ELISA employed in the bovine viral diarrhoea virus (BVDV) eradication programme in Scandinavia in the 1990s.

For most of his time at MRI he led a team investigating chlamydial abortion in sheep and identification of Th1-type responses as immune correlates of protection for novel sub-unit vaccine design. He managed a cross-Institute Work Package within the Scottish Government Strategic Research Programme until his departure from MRI in 2019.   

Gary was awarded an Honorary Professorship within the College of Medicine and Veterinary Medicine at The University of Edinburgh in 2008, a position he still holds. He has been active in a number of Committees, including Chair of the International Union of Immunological Societies Veterinary Immunology Committee (2013-2019). He is currently a member of the Scientific Committee of the STAR-IDAZ International Research Consortium (2017-2022) and Congress Secretary of the British Society for Immunology (2017-2021) and maintains his interests in vaccinology and ruminant immunology.

Professor Stephen Inglis was Director of the National Institute for Biological Standards and Control for 14 years until 2016.  NIBSC’s role is to assure the quality of existing and new biological medicines through applied research on their safety and efficacy, development of tools for their measurement, and regulatory testing of manufactured products for release on to the market. 

After a degree in biochemistry from Aberdeen and a Cambridge Ph.D. working on the molecular biology of influenza virus, he spent ten years as a lecturer in the Department of Pathology, Cambridge University, specializing in RNA viruses.  In 1990 he moved into the biotechnology industry, developing novel vaccines and biotherapeutics as one of the founders of Cantab Pharmaceuticals, and becoming Research Director in 1995.

At NIBSC he played a key role in particular in shaping its influenza and advanced therapies programmes as well as overseeing successive mergers with the HPA and MHRA.  He has served on many national advisory committees, including the Joint Vaccination and Immunisation Committee, Joint Professional Advisory Committee to the UK Blood Services and Scientific Pandemic Influenza Advisory Group.  He also played an important role internationally as Director of the leading WHO Collaborating Laboratory for Standards and a member of the WHO’s Global Vaccine Action Plan Monitoring Group.

He holds an Honorary Professorship in the Division of Infection and Immunity at University College London, a visiting Fellowship at the National Institutes for Food and Drug Control, Beijing, and received a CBE in the 2017 New Year’s Honours List.

For more than 30 years Thomas Mettenleiter has performed research primarily on herpesviruses, in particular herpesviruses of animals. He has trained as a molecular biologist at Tübingen university from 1977-1982, then started his PhD work at the then Federal Research Centre for Virus Diseases of Animals (the current Friedrich-Loeffler-Institut).    

After obtaining a PhD with studies on pseudorabies virus (PrV) glycoproteins he went to performed research at Vanderbilt University, Nashville, USA for 18 months to continue his work on PrV in collaboration with Professor Tamar Ben-Porat, then the world's leading PrV researcher.  After his return he was appointed director of the department of molecular and cellular virology at Insel Riems.  His scientific studies on the molecular biology and pathogenesis of animal herpesviruses provided important results to understand the structure, replication, virulence and tropism of herpesviruses and for the development of novel vaccines.  His results contributed to the first development of marked vaccines and, thus, for the efficient control and eradication of Aujeszky's disease in pigs.

Since 1997 he is president of the Friedrich-Loeffler-Institut (FLI), Federal Research Institute for Animal Health, with headquarters on the Isle of Riems close to Greifswald, the world's oldest virological research institute. The FLI has been designated a Collaborative Center for Zoonoses in Europe of the World Organization of Animal Health (OIE).  He is a member of the German academy of sciences Leopoldina, the Polish Academy of Science, the Belgian Royal Medical Society and the Academy of Science in Hamburg.  In addition, he holds an honorary doctorate in veterinary medicine awarded from the veterinary university at Hannover, Germany and was awarded the Robert von Ostertag-Medal, the highest distinction of the German Veterinary Association.  He has published around 400 peer reviewed papers in high ranking journals mostly on PrV and other animal herpesviruses but also on influenza, rhabdo, paramyxo and other viruses.  He remains devoted to the study of PrV as a model for herpesvirus infection and as an important infectious agent for animal husbandry.

Professor John Pickett is a British chemist who is noted for his work on insect pheromones.

Professor Pickett completed BSc and PhD degrees at the University of Surrey and was a post-doctoral researcher in organic chemistry at UMIST before joining the Brewing Research Foundation.

In 1976, he moved to Rothamsted Experimental Station (now Rothamsted Research), studying ways to control insect pests by modifying behavioural activity. He was appointed Head of the Insecticides and Fungicides Department (later the Biological Chemistry Department) in 1984, and Director of the Centre for Sustainable Pest and Disease Management in 2007.

He has also been a Special Professor at the University of Nottingham since 1991, and an Honorary Member of the Academic Staff at the University of Reading since 1995. He was elected a Fellow of the Royal Society in 1996 and a Foreign Associate of the National Academy of Sciences (US) in 2014.

He was awarded a share of the 2008 Wolf Prize in Agriculture "for their remarkable discoveries of mechanisms governing plant-insect and plant-plant interactions. Their scientific contributions on chemical ecology have fostered the development of integrated pest management and significantly advanced agricultural sustainability”. He delivered the Croonian Lecture the same year to the Royal Society on Plant and Animal Communication.

Professor Rowlands is an emeritus Professor of Molecular Virology at the University of Leeds. He worked at the Animal Virus Research Institute (now The Pirbright Institute), before transferring to industry, holding positions at Wellcome Biotech and the Wellcome Foundation and finally moved into academia at the University of Leeds. He has a lifetime of experience studying both human and animal viruses. 

Helen Sang received a degree in Natural Sciences and PhD in genetics from Cambridge University. She continued developing a research career with the award of an SERC-NATO Fellowship held at Harvard University and an MRC Fellowship held at Edinburgh University.

Helen was then appointed as a Principal Investigator at The Roslin Institute, now part of the University of Edinburgh. Her main research focus at The Roslin Institute has been the development of technologies for genetic modification of the chicken, which are applied in basic biomedical research, biotechnology and investigating the potential for developing disease resistance in production chickens. Professor Helen Sang was appointed Personal Chair in Vertebrate Molecular Development in 2009. Her research has been supported by grants from the BBSRC, MRC, Wellcome Trust and industry.

In addition to her research, Helen has a strong commitment to Public Engagement with Research and lead the Roslin Institute’s Athena SWAN (gender equality) activities, resulting in achieving a gold award. Helen has been a member of several BBSRC committees and BBSRC Council, and is currently a member of the UKRI-BBSRC’s Appointments Board. She is a Fellow of the Royal Society of Biology and the Royal Society of Edinburgh and was awarded an OBE in 2019 for services to food security and bioscience for health.

 Geoffrey L. Smith is Professor of Pathology at the University of Cambridge. He obtained his PhD (1981) for work with influenza virus in Alan Hay’s laboratory at NIMR, London. Then as a postdoc in Bernard Moss’s laboratory at NIH, USA (1981-84), together with Michael Mackett, he developed vaccinia virus (the smallpox vaccine) as an expression vector and established the principal of using genetically engineered viruses as live vaccines. He continued working with poxviruses in UK at Cambridge (1985-9), Oxford (1989-2000), Imperial College London (2000-11) and since 2011 back in Cambridge. His research studies the interactions of poxviruses with the host cell and immune system.

Current external roles include Chairmanship of the WHO Advisory Committee for Variola Virus (smallpox) Research (2004-) and the Scientific Advisory Board of the Centre for Structural and Systems Biology, Hamburg, and a member of the University Research Grants Council, Hong Kong. Formerly, he was President of IUMS, Chairman of the Royal Society Committee for Scientific Aspects of International Security, Chairman of the Scientific Advisory Board of the Friedrich-Loeffler Institute (German Ministry for Food and Agriculture), a member of the Royal Society Science Policy Advisory Group, and a Governor of the Lister Institute of Preventive Medicine. He was elected a Fellow of the Academy of Medical Sciences (2002), the Institute of Biology (2002), the Royal Society (2003), a Founding Member of the European Academy of Microbiology (2008) and a member of Leopoldina - the German National Academy of Sciences (2011).

Samuel Thevasagayam leads the Livestock initiative within the Agriculture Development Program at the Bill & Melinda Gates Foundation where he oversees the implementation of foundation’s strategy in animal health, animal production and livestock systems. Sam joined the Gates Foundation in 2012.

Samuel started his career as a small animal clinician and lecturer at the University of Peradeniya, Sri Lanka. He then went on to work in academic research, Pharmaceutical R&D (veterinary and human), Business Development and within the not-for profit sector, living and working in four continents before joining the Gates Foundation.  

Samuel graduated from the faculty of Veterinary Medicine and Animal Sciences of the University of Peradeniya, Sri Lanka. Gained his PhD in veterinary virology from the University of Hertfordshire for his research on foot-and-mouth disease virus at The Pirbright Institute and holds an MBA from the University of Oxford. He is a Charted Biologist and a Fellow of the Royal Society of Biology.